Clinical trial
A Phase 2, Multicenter, Randomized, Double-Blind, Vehicle Controlled, Clinical Study to Compare the Safety and Efficacy of IDP-126 Gel to Epiduo® Forte Gel (0.3% Adapalene/2.5% BPO), in the Treatment of Acne Vulgaris
NCT04892706 is registered in ClinicalTrials.gov with Bausch Health Americas, Inc. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 2, Multicenter, Randomized, Double-Blind, Vehicle Controlled, Clinical Study to Compare the Safety and Efficacy of IDP-126 Gel to Epiduo® Forte Gel (0.3% Adapalene/2.5% BPO), in the Treatment of Acne Vulgaris
- Lead sponsor
- Bausch Health Americas, Inc.
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- June 11, 2021
- Completion date
- September 28, 2022
- Enrollment
- 686 (actual)
- Sites
- 42
Conditions
As the registry lists them; a condition with its own page is linked.